Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Baim Institute for Clinical Research, Boston, Massachusetts.
JAMA Netw Open. 2023 Apr 3;6(4):e239638. doi: 10.1001/jamanetworkopen.2023.9638.
The underuse of oral anticoagulation in patients with nonvalvular atrial fibrillation (AF) is a major issue that is not well understood.
To understand the lack of anticoagulation by assessing the perceptions of patients with AF who are not receiving anticoagulation and their physician's about the risk of stroke and the benefits and risks of anticoagulation.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with nonvalvular AF and a CHA2DS2-VASc score of 2 or more (calculated as congestive heart failure, hypertension, age 75 years and older, diabetes, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) who were not receiving anticoagulation and were enrolled from 19 sites within the National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence Registry (PINNACLE Registry) between January 18, 2017, and May 7, 2018. Data were collected from January 18, 2017, to September 30, 2019, and analyzed from April 2022 to March 2023.
Each patient enrolled in the study completed a survey, and their treating physician then conducted a clinical review of their care.
Assessment of willingness for anticoagulation treatment and its appropriateness after central review by a panel of 4 cardiologists. Use of anticoagulation at 1 year follow-up was compared vs similar patients at other centers in the PINNACLE Registry.
Of the 817 patients enrolled, the median (IQR) age was 76.0 (69.0-83.0) years, 369 (45.2%) were women, and the median (IQR) CHA2DS2-VASc score was 4.0 (3.0-6.0). The top 5 reasons physicians cited for no anticoagulation were low AF burden or successful rhythm control (278 [34.0%]), patient refusal (272 [33.3%]), perceived low risk of stroke (206 [25.2%]), fall risk (175 [21.4%]), and high bleeding risk (167 [20.4%]). After rereview, 221 physicians (27.1%) would reconsider prescribing oral anticoagulation as compared with 311 patients (38.1%), including 67 (24.6%) whose physician cited patient refusal. Of 647 patients (79.2%) adjudicated as appropriate or may be appropriate for anticoagulation, physicians would reconsider anticoagulation for only 177 patients (21.2%), while 527 patients (64.5%) would either agree to starting anticoagulation (311 [38.1%]) or were neutral (216 [27.3%]) to starting anticoagulation. Upon follow-up, 119 patients (14.6%) in the BOAT-AF study were prescribed anticoagulation, as compared with 55 879 of 387 975 similar patients (14.4%) at other centers in the PINNACLE Registry.
The findings of this cohort study suggest that patients with AF who are not receiving anticoagulation are more willing to consider anticoagulation than their physicians. These data emphasize the need to revisit any prior decision against anticoagulation in a shared decision-making manner.
非瓣膜性心房颤动(AF)患者口服抗凝剂的使用不足是一个主要问题,目前尚未得到很好的理解。
通过评估未接受抗凝治疗的 AF 患者及其医生对中风风险以及抗凝治疗的益处和风险的看法,了解抗凝治疗不足的情况。
设计、地点和参与者:这项队列研究纳入了非瓣膜性 AF 且 CHA2DS2-VASc 评分为 2 或更高(计算方法为充血性心力衰竭、高血压、年龄 75 岁及以上、糖尿病、中风或短暂性脑缺血发作、血管疾病、65 至 74 岁和性别类别)且未接受抗凝治疗的患者,并从全国心血管数据注册(NCDR)实践创新和临床卓越登记(PINNACLE 登记)的 19 个地点招募,招募时间为 2017 年 1 月 18 日至 2018 年 5 月 7 日。数据收集时间为 2017 年 1 月 18 日至 2019 年 9 月 30 日,分析时间为 2022 年 4 月至 2023 年 3 月。
每位入组患者均完成了一项调查,随后他们的主治医生对他们的治疗情况进行了临床审查。
由 4 名心脏病专家组成的小组对治疗意愿及其适当性进行了中心审查评估。在 1 年随访期间,与 PINNACLE 登记处其他中心的类似患者相比,使用抗凝治疗的情况。
在 817 名入组患者中,中位(IQR)年龄为 76.0(69.0-83.0)岁,369 名(45.2%)为女性,中位(IQR)CHA2DS2-VASc 评分为 4.0(3.0-6.0)。医生未开具抗凝剂的前 5 个原因是房颤负担低或节律控制成功(278 [34.0%])、患者拒绝(272 [33.3%])、认为中风风险低(206 [25.2%])、跌倒风险(175 [21.4%])和高出血风险(167 [20.4%])。重新审查后,221 名医生(27.1%)与 311 名患者(38.1%)相比会重新考虑开口服抗凝剂,其中 67 名医生(24.6%)因患者拒绝而重新考虑。在 647 名(79.2%)被判定为适当或可能适合抗凝的患者中,医生只会重新考虑为 177 名患者(21.2%)开抗凝剂,而 527 名患者(64.5%)要么同意开始抗凝(311 [38.1%]),要么对开始抗凝持中立态度(216 [27.3%])。在随访期间,BOAT-AF 研究中有 119 名患者(14.6%)接受了抗凝治疗,而在 PINNACLE 登记处的其他 387959 名类似患者中(14.4%),有 55 名患者接受了抗凝治疗。
这项队列研究的结果表明,未接受抗凝治疗的 AF 患者比他们的医生更愿意考虑抗凝治疗。这些数据强调需要以共同决策的方式重新考虑之前任何反对抗凝的决定。